Conference Coverage

Model could reduce some disparities in lung cancer screening


 

FROM WCLC 2020

More and widening disparity

The results showed that augmenting USPSTF criteria to include high-benefit people selected significantly more African Americans than Whites and could therefore reduce or even eliminate disparities between Whites and African Americans.

“The 2020 USPSTF draft recommendations would make 6.5 million more people eligible to be screened, in addition to the 8 million from the 2013 criteria,” said Gerard Silvestri, MD, of the Medical University of South Carolina, Charleston, who was not involved in this study.

“But there will be more White people than African American people added, and the disparity between them may widen. Using the risk prediction model outlined in this well-researched study could close the gap in disparity. It’s important to identify individual risk and life expectancy.”

Dr. Silvestri pointed out that, compared to Whites, African Americans develop lung cancer at an earlier age with fewer pack-years history of smoking and have worse outcomes.

“We can’t just focus on one aspect of disparity,” he said. “African Americans are much less likely to be insured or to identify a primary care provider for integrated care. We know that screening works. The 2020 USPSTF draft recommendations will enlarge the pool of eligible African Americans and reduce disparities if the other part of the equation holds; that is, they get access to care and screening.”

This study was funded by the National Institutes of Health/National Cancer Institute. Dr. Landy and Dr. Silvestri have no disclosures.

Pages

Recommended Reading

AI can identify biomarkers and potentially guide therapy in NSCLC
Federal Practitioner
COVID-19 vaccination in cancer patients: NCCN outlines priorities
Federal Practitioner
Pandemic seems to impact lung cancer diagnosis and prognosis
Federal Practitioner
Screening for lung cancer in never-smokers is ‘feasible’
Federal Practitioner
Nivolumab improves survival in relapsed mesothelioma
Federal Practitioner
‘Astonishing’ 4-year survival in NSCLC with pembro plus chemo
Federal Practitioner
Death rates ‘remain high’ in patients with thoracic cancers and COVID-19
Federal Practitioner
Managing cancer outpatients during the pandemic: Tips from MSKCC
Federal Practitioner
Neoadjuvant atezolizumab safe for patients with resectable lung cancer
Federal Practitioner
Customized chemotherapy did not improve survival in early NSCLC
Federal Practitioner